Amgen sues FDA to get paediatric exclusivity for Sensipar

Amgen has filed a complaint against the US Food and Drug Administration (FDA) for not accepting its study reports and denying six months of paediatric exclusivity for its drug Sensipar (cinacalcet).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hikma triumphs at SCOTUS in landmark skinny-label ruling

4 June 2026 Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.

Americas

Heated LNP litigation puts Moderna and Acuitas in the spotlight

3 June 2026 A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.

Americas

J&J unit's valuable heart pump saved by 'rare' patent defence

1 June 2026 A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.

More features

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Dehns appoints head of litigation following wave of senior hires

Chadha & Chadha hires former Remfry & Sagar patent partner

Heated LNP litigation puts Moderna and Acuitas in the spotlight

UPC dispute resolution forum opens with ceremony in Slovenia

J&J unit's valuable heart pump saved by 'rare' patent defence

Kirkland & Ellis adds leading barrister in London

Amgen sues FDA to get paediatric exclusivity for Sensipar

More on this story

Editor's picks

Editor's picks

More features